Sarthak Metal’s FY24 Report Card: Building for the future in a tough year

Sarthak Metal’s core business of supplying certain consumables – cored wires and aluminium flipping coils – for the manufacture of steel continued to suffer headwinds in FY24. For the second year in a row revenue fell, coming down to Rs 305 crore in FY24 as compared to Rs 408 crore…

Read More

2023 was the year of new business decisions at Sarthak Metals

The management of Sarthak Metals announced two new areas for expansion in 2023. The backdrop to this is: the management was evaluating options for expansion for some time. In its main business of making two key consumables for manufacture of steel – cored wire and aluminium flipping coils –   the…

Read More

Indrayani Biotech – A growth stock to watch out for

Indrayani Biotech (BSE: 526445) is a growth stock that is likely to show strong double digit growth over the next few years. In its Annual Report released the last week, the company has projected a consolidated revenue of Rs 150 crore for FY23. In comparison, the revenue for FY22 was Rs…

Read More

Sharp drop in Global Biotech VC investments

2022 is witnessing a sharp drop in global biotech investments by venture capital funds. Data compiled by Wisdomsmith shows venture capital funds invested $15.8B in biotech and healthcare sector over Jan-Apr’22, as compared to $27B over the same period in 2021. That’s a drop of 41%.   While the drop…

Read More

USD 3.3B of VC/PE investment in lifesciences firms in Sep’21

We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…

Read More

USD 6.5B of VC/PE investment in lifesciences firms in June’21

We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…

Read More

USD 6.6B of VC/PE investment in lifesciences firms in May’21

We recorded 94 VC/PE transactions pertaining to the global life sciences sector for May 2021, aggregating to a sum of USD 6.56B. The USA recorded 60 transactions aggregating to a total investment of USD 3.3B. China reported investment of USD 1.8B from 12 VC/PE transactions. Rest of the world accounted…

Read More

USD 6.5B of VC/PE investment in lifesciences firms in Apr’21

We recorded 131 VC/PE transactions pertaining to the global life sciences sector for April 2021, aggregating to a sum of USD 6.5B. The USA recorded 88 transactions with total investment of USD 3.8B. China reported investment of USD 585m from 12 VC/PE transactions. Rest of world accounted for 31 transactions…

Read More

USD 9.2B of VC/PE investment in lifescience firms in Mar’21

We recorded 130 VC/PE transactions pertaining to the global life sciences sector for March 2021, aggregating to a sum of USD 9.2B. This is an all-time high deal count as well as amount. The USA recorded 86 transactions with total investment of USD 6.3B. China reported investment of USD 1.7B…

Read More

BeiGene bags blockbuster deal with Anti-PD-1 Antibody Tislelizumab

BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene  $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…

Read More